Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 3/20 | 0.38 |
| ▸ | FASN | P49327 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.36 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.36 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.36 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.36 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.36 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.36 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1020791 | 0.86 | KDM1A (0.43) | EPHX2KMT2ATP53MAPTMEN1 | |
| SCHEMBL348149 | 0.85 | EPHX2 (0.45) | EPHX2KMT2ATP53MAPTMEN1 | |
| SCHEMBL347867 | 0.85 | TP53 (0.43) | EPHX2KMT2ATP53MAPTMEN1 | |
| SCHEMBL347102 | 0.84 | NPC1 (0.44) | EPHX2KMT2AKCNH2MCHR1PRKAA2 | |
| SCHEMBL348833 | 0.83 | HRH3 (0.40) | EPHX2KMT2AFASNKCNH2MCHR1 | |
| SCHEMBL15310312 | 0.78 | EPHX2 (0.44) | EPHX2KMT2AMAPTMEN1KCNH2 | |
| SCHEMBL12955061 | 0.77 | MCHR1 (0.43) | KMT2ATP53MAPTMEN1MCHR1 | |
| SCHEMBL12954855 | 0.77 | FAAH (0.50) | TP53MAPTMCHR1PRKAA2 | |
| SCHEMBL348234 | 0.77 | L3MBTL1 (0.42) | EPHX2KMT2AFASNPRKAA2PRKAB2 | |
| SCHEMBL347913 | 0.76 | TSHR (0.43) | EPHX2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759352-B2 | 1-(4-ureidobenzoyl)piperazine derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-06-24 | — | — | US | disclosed |
| EP-2318368-B1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | MERCK SHARP & DOHME (NL) | 2013-10-16 | — | — | EP | disclosed |
| US-20120015958-A1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | N.V. ORGANON (NL) | 2012-01-19 | — | — | US | disclosed |
| US-20110286969-A1 | DEUTERATED COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | SCHERING CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015958-A1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | NPC1, ABCB11, NPC1L1 | EPHX2 1501/4885KMT2A 4136/4885TP53 4394/4885 |
| US-20110286969-A1 | DEUTERATED COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | PEPD, PREP, ACE | EPHX2 1554/4885KMT2A 2471/4885TP53 2528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.